{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreib4y6gsc5s5lisx2lxbfwz4r4y2wgi6sxixfjax4jie2eqinsou4m",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mk2idnxsuul2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiazbsrzzmncrbfhfv2kbbvmbv6akffxjwsxdhrlcnqog4rprxywte"
    },
    "mimeType": "image/jpeg",
    "size": 43322
  },
  "path": "/2026/04/21/kyverna-therapeutics-stiff-person-syndrome/?utm_campaign=rss",
  "publishedAt": "2026-04-21T22:45:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "biotechnology",
    "chronic disease",
    "drug development",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in a late-stage trial.",
  "title": "STAT+: Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval",
  "updatedAt": "2026-04-21T19:42:06.000Z"
}